Sterol regulatory element-binding protein

Protein family

Sterol regulatory element binding proteins (SREBPs) are transcription factors that bind to the sterol regulatory element DNA sequence TCACNCCAC. Mammalian SREBPs are encoded by the genes SREBF1 and SREBF2. SREBPs belong to the basic helix loop helix leucine zipper class of transcription factors. Unactivated SREBPs are attached to the nuclear envelope and endoplasmic reticulum membranes. In cells with low levels of sterols, SREBPs are cleaved to a water soluble N terminal domain that is translocated to the nucleus. These activated SREBPs then bind to specific sterol regulatory element DNA sequences, thus upregulating the synthesis of enzymes involved in sterol biosynthesis. Sterols in turn inhibit the cleavage of SREBPs and therefore synthesis of additional sterols is reduced through a negative feed back loop.

Animal cells maintain proper levels of intracellular lipids (fats and oils) under widely varying circumstances (lipid homeostasis). For example, when cellular cholesterol levels fall below the level needed, the cell makes more of the enzymes necessary to make cholesterol. A principal step in this response is to make more of the mRNA transcripts that direct the synthesis of these enzymes. Conversely, when there is enough cholesterol around, the cell stops making those mRNAs and the level of the enzymes falls. As a result, the cell quits making cholesterol once it has enough. A notable feature of this regulatory feedback machinery was first observed for the SREBP pathway regulated intramembrane proteolysis (RIP). Subsequently, RIP was found to be used in almost all organisms from bacteria to human beings and regulates a wide range of processes ranging from development to neurodegeneration. A feature of the SREBP pathway is the proteolytic release of a membrane bound transcription factor, SREBP. Proteolytic cleavage frees it to move through the cytoplasm to the nucleus. Once in the nucleus, SREBP can bind to specific DNA sequences (the sterol regulatory elements or SREs) that are found in the control regions of the genes that encode enzymes needed to make lipids. This binding to DNA leads to the increased transcription of the target genes. The ~120 kDa SREBP precursor protein is anchored in the membranes of the endoplasmic reticulum (ER) and nuclear envelope by virtue of two membrane spanning helices in the middle of the protein. The precursor has a hairpin orientation in the membrane, so that both the amino terminal transcription factor domain and the COOH terminal regulatory domain face the cytoplasm. The two membrane spanning helices are separated by a loop of about 30 amino acids that lies in the lumen of the ER. Two separate, site specific proteolytic cleavages are necessary for release of the transcriptionally active amino terminal domain. These cleavages are carried out by two distinct proteases, called site 1 protease (S1P) and site 2 protease (S2P). In addition to S1P and S2P, the regulated release of transcriptionally active SREBP requires the cholesterol sensing protein SREBP cleavage activating protein (SCAP), which forms a complex with SREBP owing to interaction between their respective carboxy terminal domains. SCAP, in turn, can bind reversibly with another ER resident membrane protein, INSIG. In the presence of sterols, which bind to INSIG and SCAP, INSIG and SCAP also bind one another. INSIG always stays in the ER membrane and thus the SREBP SCAP complex remains in the ER when SCAP is bound to INSIG. When sterol levels are low, INSIG and SCAP no longer bind. Then, SCAP undergoes a conformational change that exposes a portion of the protein ('MELADL') that signals it to be included as cargo in the COPII vesicles that move from the ER to the Golgi apparatus. In these vesicles, SCAP, dragging SREBP along with it, is transported to the Golgi. The regulation of SREBP cleavage employs a notable feature of eukaryotic cells, subcellular compartmentalization defined by intracellular membranes, to ensure that cleavage occurs only when needed. Once in the Golgi apparatus, the SREBP SCAP complex encounters active S1P. S1P cleaves SREBP at site 1, cutting it into two halves. Because each half still has a membrane spanning helix, each remains bound in the membrane. The newly generated amino terminal half of SREBP (which is the ‘business end' of the molecule) then goes on to be cleaved at site 2 that lies within its membrane spanning helix. This is the work of S2P, an unusual metalloprotease. This releases the cytoplasmic portion of SREBP, which then travels to the nucleus where it activates transcription of target genes (e. g. LDL receptor gene)

Absence of sterols activates SREBP, thereby increasing cholesterol synthesis. Insulin, cholesterol derivatives, T3 and other endogenous molecules have been demonstrated to regulate the SREBP1c expression, particularly in rodents. Serial deletion and mutation assays reveal that both SREBP (SRE) and LXR (LXRE) response elements are involved in SREBP 1c transcription regulation mediated by insulin and cholesterol derivatives. Peroxisome proliferation activated receptor alpha (PPARα) agonists enhance the activity of the SREBP 1c promoter via a DR1 element at 453 in the human promoter. PPARα agonists act in cooperation with LXR or insulin to induce lipogenesis. A medium rich in branched chain amino acids stimulates expression of the SREBP 1c gene via the mTORC1/S6K1 pathway. The phosphorylation of S6K1 was increased in the liver of obese db/db mice. Furthermore, depletion of hepatic S6K1 in db/db mice with the use of an adenovirus vector encoding S6K1 shRNA resulted in down regulation of SREBP 1c gene expression in the liver as well as a reduced hepatic triglyceride content and serum triglyceride concentration. mTORC1 activation is not sufficient to stimulate hepatic SREBP 1c in the absence of Akt signaling, revealing the existence of an additional downstream pathway also required for this induction which is proposed to involve mTORC1 independent Akt mediated suppression of INSIG 2a, a liver specific transcript encoding the SREBP 1c inhibitor INSIG2. FGF21 has been shown to repress the transcription of sterol regulatory element binding protein 1c (SREBP 1c). Overexpression of FGF21 ameliorated the up regulation of SREBP 1c and fatty acid synthase (FAS) in HepG2 cells elicited by FFAs treatment. Moreover, FGF21 could inhibit the transcriptional levels of the key genes involved in processing and nuclear translocation of SREBP 1c, and decrease the protein amount of mature SREBP 1c. Unexpectedly, overexpression of SREBP 1c in HepG2 cells could also inhibit the endogenous FGF21 transcription by reducing FGF21 promoter activity. SREBP 1c has also been shown to upregulate in a tissue specific manner the expression of PGC1alpha expression in brown adipose tissue. Nur77 is suggested to inhibit LXR and downstream SREBP 1c expression modulating hepatic lipid metabolism.

The SREBPs were elucidated in the laboratory of Nobel laureates Michael Brown and Joseph Goldstein at the University of Texas Southwestern Medical Center in Dallas. Their first publication on this subject appeared in October 1993.